Quantcast

Latest Oasmia Pharmaceutical AB Stories

2010-07-15 01:59:00

UPPSALA, Sweden, July 15, 2010 /PRNewswire-FirstCall/ -- - A Number of Promising New Product Candidates for Cancer Treatment, Within Both Human and Veterinary Oncology ABOUT OASMIA Oasmia is developing a new generation of drugs with emphasis on human and veterinary oncology. Our main business activity focuses on improving product life cycles and the versatility of current pharmaceuticals. In-house research in nanotechnology and a long-term working basis can be seen as a...

2009-07-10 08:00:00

ABBOTT PARK, Ill. and UPPSALA, Sweden, July 10 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Oasmia Pharmaceutical have announced a multi-year agreement to market one of the first cancer medications for dogs. The chemotherapeutic agent, called Paccal(R) Vet (micellar paclitaxel), represents the first generation of treatments of its kind and is currently being studied to treat Grade II and Grade III canine mast cell tumors where curative surgery cannot be performed. Under the terms of...

2009-04-14 05:20:00

UPPSALA, Sweden, April 14 /PRNewswire-FirstCall/ -- Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer. Orphan Drug designation can entail additional assistance from FDA to expedite and optimize drug development and upon approval a seven year market exclusivity is granted. (Logo: http://www.newscom.com/cgi-bin/prnh/20070918/273312 ) Orphan drug designation is intended to support the...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.